Moderna Inc (MRNA)vsNeurosense Therapeutics Ltd (NRSN)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NRSN
Neurosense Therapeutics Ltd
$0.35
+4.58%
HEALTHCARE · Cap: $19.29M
Smart Verdict
WallStSmart Research — data-driven comparison
NRSN leads profitability with a 0.0% profit margin vs -141.4%. NRSN earns a higher WallStSmart Score of 21/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NRSN
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NRSN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NRSN
The strongest argument for NRSN centers on Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NRSN
The primary concerns for NRSN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NRSN is a value play — different risk/reward profiles.
NRSN carries more volatility with a beta of 1.58 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NRSN generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 21/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Neurosense Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?